Company profile
Gilead Sciences, Inc.
NASDAQ: GILD · Healthcare · Drug Manufacturers - General
#21 of 1,418 Healthcare companies by revenue46th-percentile growth
EA Score
87AFH 94DQ 86GM 62SS 97
v0.1 · 65/100 weight · provisional
↑ Piotroski F, market scale · ↓ revenue growth (YoY), 3-yr revenue growth
Methodology →Revenue TTM
$29.7B
Rev growth YoY (TTM)
+3.5%
Net income (FY)
$8.5B
Employees
17,000
as of 2026-08-04
Market cap
$162.8B
as of 2026-08-04
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$29.4B$29.4B2025
Net income$8.5B$8.5B2025
Operating income$10.0B$10.0B2025
Total assets$59.0B$59.0B2025
Equity$22.7B$22.7B2025
Revenue trend
FY2020 – FY2025 · USD
FY20
FY20
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2025
By product
Products, Other HIV80%
Cell Therapy Products, Total Cell Therapy Product Sales8%
Trodelvy5%
Veklury3%
Other Products, Total Other product sales3%
By geography
UNITED STATES71%
Europe17%
Other International12%
The read
What is Gilead Sciences, Inc.’s revenue?
Gilead Sciences, Inc. booked $29.4B in FY2025 revenue, growing 2.4% year over year — about the middle of the pack among Healthcare companies we track, at a 28.9% net margin.
Peers · Healthcare
Abbott Laboratories87AAmgen Inc.88AMedtronic plc84B+Medline Inc.62CStryker Corporation87ADanaher Corporation87ANeighbors
San Mateo →Key facts
CEODaniel O'Day
SectorHealthcare
IndustryDrug Manufacturers - General
HeadquartersFoster City, CA
ExchangeNASDAQ: GILD
Employees17,000
IPO date1992-01-22
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.